The new guidelines urge health professionals to move away from short-acting beta2 agonists (SABA) – commonly known as blue puffers – as a stand-alone treatment for adults and adolescents over the age ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback